Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.69 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.69 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13539737 | 0.88 | HSP90AA1 (0.84) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3391730 | 0.87 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3396006 | 0.86 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL12614315 | 0.86 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3396148 | 0.85 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL3392846 | 0.84 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL14568026 | 0.84 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL13539440 | 0.84 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL13539715 | 0.83 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL13539731 | 0.83 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1TRAP1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070105874-A1 | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105874-A1 | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2007035963-A2 | ANTI-TUMOR METHODS USING MULTI DRUG RESISTANCE INDEPENDENT SYNTHETIC HSP90 INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-03-29 | — | — | WO | disclosed |
| US-7138402-B2 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050107343-A1 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107343-A1 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885TRAP1 11/4885 |
| US-20070105874-A1 | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885TRAP1 15/4885 |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885TRAP1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.